Judith Matthews Net Worth

The estimated Net Worth of Judith M. Matthews is at least $820 Thousand dollars as of 11 March 2022. Ms. Matthews owns over 47,132 units of Iterum Therapeutics Plc stock worth over $85,983 and over the last 6 years she sold ITRM stock worth over $168,555. In addition, she makes $565,093 as Chief Financial Officer at Iterum Therapeutics Plc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Matthews ITRM stock SEC Form 4 insiders trading

Judith has made over 4 trades of the Iterum Therapeutics Plc stock since 2018, according to the Form 4 filled with the SEC. Most recently she sold 47,132 units of ITRM stock worth $17,910 on 11 March 2022.

The largest trade she's ever made was selling 56,130 units of Iterum Therapeutics Plc stock on 30 September 2020 worth over $92,053. On average, Judith trades about 14,113 units every 138 days since 2018. As of 11 March 2022 she still owns at least 81,500 units of Iterum Therapeutics Plc stock.

You can see the complete history of Ms. Matthews stock trades at the bottom of the page.

Judith Matthews biography

Judith M. Matthews serves as Chief Financial Officer of the Company. From 2012 to February 2015, Ms. Matthews served as vice president of finance at Durata Therapeutics, Inc. From 2009 to 2012, Ms. Matthews served as head of financial planning & analysis at Bally Total Fitness Corporation, a fitness club chain. From 2004 to 2008, Ms. Matthews served as vice president of finance for the Sterno Group, a subsidiary of Blyth, Inc., a home products company. Ms. Matthews holds a B.A. in accounting from the University of Illinois at Urbana-Champaign and a Master of Management in finance and marketing from the Kellogg School of Management at Northwestern University.

What is the salary of Judith Matthews?

As the Chief Financial Officer of Iterum Therapeutics Plc, the total compensation of Judith Matthews at Iterum Therapeutics Plc is $565,093. There are 3 executives at Iterum Therapeutics Plc getting paid more, with Corey Fishman having the highest compensation of $1,392,030.

How old is Judith Matthews?

Judith Matthews is 50, she's been the Chief Financial Officer of Iterum Therapeutics Plc since 2019. There are 10 older and 2 younger executives at Iterum Therapeutics Plc. The oldest executive at Iterum Therapeutics Plc is Dr. Michael W. Dunne M.D., 61, who is the Strategic Advisor & Director.

What's Judith Matthews's mailing address?

Judith's mailing address filed with the SEC is Harcourt Centre, Harcourt St, Saint Kevin's, Dublin 2, Ireland.

Insiders trading at Iterum Therapeutics Plc

Over the last 6 years, insiders at Iterum Therapeutics Plc have traded over $51,533,386 worth of Iterum Therapeutics Plc stock and bought 4,586,895 units worth $57,505,095 . The most active insiders traders include Capital Management, L.P.Ra ..., Alexander J Sarissa Capital..., and James Healy. On average, Iterum Therapeutics Plc executives and independent directors trade stock every 38 days with the average trade being worth of $474,585. The most recent stock trade was executed by Michael W. Dunne on 6 August 2024, trading 106,247 units of ITRM stock currently worth $112,091.

What does Iterum Therapeutics Plc do?

iterum therapeutics plc is an ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. these products are aimed at combatting the global crisis of multi-drug resistant (mdr) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. for more information on iterum therapeutics please visit www.iterumtx.com.

Complete history of Ms. Matthews stock trades at Iterum Therapeutics Plc

Iterum Therapeutics Plc executives and stock owners

Iterum Therapeutics Plc executives and other stock owners filed with the SEC include:

• Corey Fishman,
  Chief Executive Officer, Director
• Corey N. Fishman,
  Pres, CEO & Director
• Michael Dunne,
  Chief Scientific Officer
• Judith Matthews,
  Chief Financial Officer
• Judith M. Matthews,
  Chief Financial Officer
• Dr. Michael W. Dunne M.D.,
  Strategic Advisor & Director
• Dr. Sailaja Puttagunta M.D.,
  Chief Medical Officer
• Brenton Ahrens,
  Independent Interim Chairman of the board
• Shahzad Malik,
  Independent Director
• David Kelly,
  Independent Director
• Ronald Hunt,
  Independent Director
• Patrick Heron,
  Independent Director
• Mark Chin,
  Independent Director
• Dr. Steven I. Aronin M.D.,
  Sr. VP & Head of Clinical Devel.
• Louise Barrett,
  Sr. VP of Legal Affairs & Sec.
• Tom Loughman Ph.D.,
  Sr. VP of Technical Operations
• Beth Hecht,
  Director
• Vijay K Ratcliffe Liam Lathi,
  
• Venture Partners Ix, L.P.Po...,
  
• James Healy,
  Director
• X L.P.Canaan Partners X Llc...,
  
• Paul R Edick,
  Director
• Jeffrey R. Schaffnit,
  Chief Commercial Officer
• Patrick J Heron,
  Director
• Capital Management, L.P.Ra ...,
  
• Healthcare Vii, L.P.Frazier...,
  
• Venture Partners Ix, L.P.So...,
  
• Venture Partners Ix, L.P.So...,
  
• Alexander J Sarissa Capital...,
  
• Sailaja Puttagunta,
  Chief Medical Officer